PL1904093T3 - Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza - Google Patents

Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza

Info

Publication number
PL1904093T3
PL1904093T3 PL06795317T PL06795317T PL1904093T3 PL 1904093 T3 PL1904093 T3 PL 1904093T3 PL 06795317 T PL06795317 T PL 06795317T PL 06795317 T PL06795317 T PL 06795317T PL 1904093 T3 PL1904093 T3 PL 1904093T3
Authority
PL
Poland
Prior art keywords
bmp
inhibition
stem cells
tumor stem
tumorigenic potential
Prior art date
Application number
PL06795317T
Other languages
English (en)
Polish (pl)
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Original Assignee
Stemgen S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S.P.A. filed Critical Stemgen S.P.A.
Publication of PL1904093T3 publication Critical patent/PL1904093T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL06795317T 2005-07-19 2006-07-19 Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza PL1904093T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP06795317.4A EP1904093B1 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by bmp-4

Publications (1)

Publication Number Publication Date
PL1904093T3 true PL1904093T3 (pl) 2018-12-31

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06795317T PL1904093T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza
PL16171392T PL3117833T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16171392T PL3117833T3 (pl) 2005-07-19 2006-07-19 Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza

Country Status (13)

Country Link
US (2) US9220756B2 (enExample)
EP (2) EP3117833B1 (enExample)
JP (3) JP5189977B2 (enExample)
KR (2) KR101311061B1 (enExample)
AU (1) AU2006271308B2 (enExample)
CA (2) CA2615491C (enExample)
DK (2) DK1904093T3 (enExample)
ES (2) ES2686093T3 (enExample)
HR (1) HRP20181379T1 (enExample)
HU (2) HUE042197T2 (enExample)
NZ (2) NZ565172A (enExample)
PL (2) PL1904093T3 (enExample)
WO (1) WO2007010394A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117833B1 (en) 2005-07-19 2019-01-23 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif
WO2009101012A1 (en) * 2008-02-13 2009-08-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
CN109311956A (zh) 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
EP3349777B1 (en) * 2015-09-17 2025-05-07 Histide AG Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrierfor converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
IL299622A (en) * 2015-09-17 2023-03-01 Histide Ag A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses
KR20180052726A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
EP3349782A2 (en) * 2015-09-17 2018-07-25 Histide AG Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof
JP7457331B2 (ja) * 2018-12-28 2024-03-28 国立大学法人 東京大学 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ATE199498T1 (de) * 1991-12-24 2001-03-15 Amrad Corp Ltd Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
ATE378407T1 (de) * 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6020141A (en) 1996-05-09 2000-02-01 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization
WO2000029012A2 (en) * 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
EP1267911A4 (en) * 2000-03-03 2004-04-21 Amrad Corp Ltd TREATMENT METHOD
JP4620052B2 (ja) 2003-09-12 2011-01-26 ステムセル テクノロジーズ インコーポレーティッド 神経コロニー形成アッセイ法
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
WO2005057172A2 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
AU2005265098B2 (en) * 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
EP3117833B1 (en) * 2005-07-19 2019-01-23 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US10130590B2 (en) * 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
WO2007010394A2 (en) 2007-01-25
US9220756B2 (en) 2015-12-29
PL3117833T3 (pl) 2019-06-28
HUE042197T2 (hu) 2019-06-28
ES2686093T3 (es) 2018-10-16
CA2790675A1 (en) 2007-01-25
EP3117833A1 (en) 2017-01-18
DK1904093T3 (en) 2018-09-03
CA2615491C (en) 2016-11-29
WO2007010394A3 (en) 2007-08-30
KR101338533B1 (ko) 2013-12-12
ES2710601T3 (es) 2019-04-26
HUE040063T2 (hu) 2019-02-28
US20160228511A1 (en) 2016-08-11
KR20120125990A (ko) 2012-11-19
EP1904093B1 (en) 2018-06-13
HRP20181379T1 (hr) 2018-11-16
US9737589B2 (en) 2017-08-22
KR20080082595A (ko) 2008-09-11
JP2012107063A (ja) 2012-06-07
JP2009502771A (ja) 2009-01-29
CA2615491A1 (en) 2007-01-25
NZ598031A (en) 2013-11-29
EP3117833B1 (en) 2019-01-23
JP5189977B2 (ja) 2013-04-24
JP2015057452A (ja) 2015-03-26
CA2790675C (en) 2016-12-20
EP1904093A2 (en) 2008-04-02
NZ565172A (en) 2012-12-21
KR101311061B1 (ko) 2013-09-25
US20100167999A1 (en) 2010-07-01
AU2006271308B2 (en) 2012-12-20
DK3117833T3 (en) 2019-03-18
AU2006271308A1 (en) 2007-01-25
JP5891068B2 (ja) 2016-03-22

Similar Documents

Publication Publication Date Title
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL242282A0 (en) Enzyme Inhibiting Compounds
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
IL179020A0 (en) Compounds for enzyme inhibition
IL179812A0 (en) THE IMPORTANCE OF THE GENE HoxB13 FOR CANCER
ZA200707639B (en) Methods of decreasing calcification
IL187449A0 (en) Variants at chr8q24.21 confer risk of cancer
ZA200703884B (en) S-mirtazapine for the treatment of hot flush
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
HUE040063T2 (hu) Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
WO2007014250A3 (en) Abl kinase inhibition
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0605685D0 (en) Inhibition of tumour growth
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
EP1890761A4 (en) PROCESS FOR REINFORCING LIPOLYSIS
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB2426765B (en) The preparation of multipotent stem cells
EP1905445A4 (en) HUMBLER OF TUMOR GROWTH
GB0517386D0 (en) Combinations for the treatment of cancer
GB0624636D0 (en) Self shutting doors-mechanical type area of the techniques
PL115454U1 (en) Shield of the radiator combined valve
SI1948678T1 (sl) Spojine za inhibiranje encimov